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Abstract 
Background 
A limitation of current antiplatelet therapies is their inability to separate thrombotic events 
from bleeding occurrences. Better understanding of the molecular mechanisms leading to 
platelet activation is of importance for the development of improved therapies. Recently, 
protein tyrosine phosphatases (PTPs) have emerged as critical regulators of platelet function.  
Methods and Results 
This is the first report implicating the dual-specificity phosphatase 3 (DUSP3) in platelet 
signaling and thrombosis. This phosphatase is highly expressed in human and mouse 
platelets. Platelets from DUSP3-deficient mice displayed a selective impairment of 
aggregation and granule secretion mediated through the collagen receptor glycoprotein VI 
(GPVI) and the C-type lectin-like receptor 2 (CLEC-2). DUSP3-deficient mice were more 
resistant to collagen- and epinephrine-induced thromboembolism, compared to wild-type 
mice, and showed severely impaired thrombus formation upon ferric chloride-induced carotid 
artery injury. Intriguingly, bleeding times were not altered in DUSP3-deficient mice. At the 
molecular level, DUSP3 deficiency impaired Syk tyrosine phosphorylation, subsequently 
reducing phosphorylation of PLC2 and calcium fluxes. To investigate DUSP3 function in 
human platelets, a novel small-molecule inhibitor of DUSP3 was developed. This compound 
specifically inhibited collagen and CLEC-2-induced human platelet aggregation, thereby 
phenocopying the effect of DUSP3 deficiency in murine cells.  
Conclusions 
DUSP3 plays a selective and essential role in collagen- and CLEC-2-mediated platelet 
activation and thrombus formation in vivo. Inhibition of DUSP3 may prove therapeutic for 
arterial thrombosis. This is the first time a PTP, implicated in platelet signaling, has been 
targeted with a small-molecule drug. 
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Introduction 
Antiplatelet therapy has been effective in reducing the mortality and morbidity of acute 
myocardial infarction, the most common cause of death in developed countries.
1
 However, 
FDA-approved antiplatelet agents have serious side effects, including gastrointestinal 
toxicity, neutropenia, thrombocytopenia, and the common bleeding.
1
 There also remains a 
considerable incidence of arterial thrombosis in patients receiving currently available 
antiplatelet therapy.
1
 A better understanding of the molecular mechanisms leading to platelet 
activation will be essential for the development of new therapeutics.  
Platelet activation depends on rapid phosphorylation and dephosphorylation of key signaling 
proteins, in particular on tyrosine.
2
 While the repertoire of protein tyrosine kinases (PTKs) 
has been well described in platelet activation, the expression, regulation, specificity, and 
function of platelet-expressed protein tyrosine phosphatases (PTPs) are largely unknown. A 
recent proteomic analysis found that 14 out of 37 classical, phosphotyrosine (pY)-specific  
PTPs are expressed in human platelets.
3
 Expression and function of the dual-specificity 
phosphatases (DSPs),
4, 5
 the largest subgroup of the PTP superfamily, are unexplored.  
DUSP3, also known as Vaccinia H1-related (VHR) phosphatase, is a DSP encoded by the 
DUSP3/Dusp3 gene. DUSP3 (185 amino acids; Mr 21 kDa), which only contains a catalytic 
(PTP) domain,
6
 has been reported to dephosphorylate the mitogen-activated protein kinases 
(MAPKs) ERK1/2 and JNK1/2.
7
 Additional reported substrates include EGFR and ErbB2.
8
 
DUSP3 is implicated in cell cycle regulation, and its expression is altered in human cancer.
9-
11
 However, since all of these studies were performed either in vitro, using recombinant 
proteins, or in cell lines, using transient overexpression or siRNA knockdown, the true 
physiological function of DUSP3 has remained elusive. We recently generated a full Dusp3-
knockout (Dusp3-KO) mouse.
12
 Dusp3-KO mice were healthy, fertile, and showed no 
spontaneous phenotypic abnormality. However, DUSP3 deficiency prevented neo-
 7 
angiogenesis and bFGF-induced microvessel outgrowth.
12
 In the present study, we identified 
DUSP3 as a key and non-redundant player in GPVI- and CLEC-2-mediated signaling 
pathways in mouse and human platelets. We show that DUSP3 deficiency limits platelet 
activation and arterial thrombosis. Moreover, we developed a specific small-molecule 
inhibitor of DUSP3, which was able to phenocopy DUSP3 deficiency in platelets.  
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Methods 
Platelet RNA sampling and Microarray   
Platelets from 256 healthy volunteers were isolated from citrate-anticoagulated blood. Donors 
were informed about the objectives of the study and signed an informed consent. The study 
was approved by the ethical committee review board of the Liège University Hospital. RNA 
extraction and microarray procedures are described in the Supplementary Material.  
Mice 
C57BL/6-Dusp3-KO were generated by homologous recombination.
12
 Heterozygous mice 
were mated to generate +/+ and −/− littermates used for experimentation (8-12 weeks old 
male mice). All experiments were approved by the local ethics committee. 
Isolation of human and mouse platelets 
Human platelets were prepared from peripheral blood freshly drawn from healthy donors as 
previously described.
13
 Mouse washed platelets (WPs) were prepared as previously 
described.
14
  
Isolation of human and murine B and T cells 
Human B and T cells were sorted from freshly collected blood using EasySep B and T cell–
negative selection kits (Stemcell Technologies). Mouse B and T cells were sorted from 
spleens. 
Platelet aggregation analyses 
Light transmission was recorded during platelet aggregation induced by collagen, convulxin 
(CVX), collagen related peptide (CRP), rhodocytin, thrombin, U46619, or ADP in the 
presence of 2 mM CaCl2 on a Lumi-Aggregometer (Chrono-log).  
Flow cytometry 
WPs were stimulated for 15 min with different concentrations of collagen, CRP, thrombin, or 
ADP under non-stirring conditions. Saturating concentrations of FITC-conjugated P-selectin 
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and PE-conjugated JON/A antibodies were added. Samples were analyzed on a FACSCantoII 
flow cytometer (BD Biosciences). 
Electron microscopy 
Platelet pellets were fixed for 60 min in 2.5% glutaraldehyde in Sörensen’s buffer (0.1 M, pH 
7.4), post-fixed for 30 min with 1% osmium tetroxide, dehydrated in a series of ethanol 
concentrations, and embedded in Epon. Ultrathin sections were stained with uranyl acetate 
and lead citrate and examined on a Jeol-CX100II transmission electron microscope (60 kV). 
Whole blood platelet aggregate formation under flow 
Thrombus formation under flow conditions was assessed with anticoagulated mouse blood (4 
U/mL heparin, 20 µM PPACK) as previously described.
15
 Area
 
coverage from phase-contrast 
images was analyzed using
 
ImagePro (Media Cybernetics).
16
 Area
 
coverage by platelets 
stained with OG488-annexin A5 was determined
 
with Quanticell (Visitech). 
Ca
2+
 flux 
Apyrase (0.5 U/mL)–treated murine WPs were loaded with 3.5 μM fura-2-acetoxymethyl 
ester in the presence of Pluronic F-127 for 15 min and fluorescence was recorded on an 
Aminco spectrofluorimeter (SLM Instruments) as described.
17
 
Arterial thrombosis models 
Pulmonary embolism was induced by injection of a mixture of collagen (170 g/kg) and 
epinephrine (60 µg/kg) into the
 
plexus retro-orbital veins of anesthetized mice (ketamine: 60 
mg/kg; xylazine: 5 mg/kg). Time to death was monitored. Lungs were perfused with 4% 
formaldehyde solution and collected for histological studies. 
Injury of carotid arteries of anesthetized mice was performed by applying a filter paper 
soaked in 10% ferric chloride (FeCl3) solution on the exposed artery for 5 min.
18
 
Fluorescence of exogenously CFSE-labeled platelets was monitored using a BX61WI 
microscope (Olympus). Digital images were captured with a Hamamatsu 9100-13 EMCCD 
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camera, using a Lambda DG-4 (Sutter instrument) light source and Slidebook software 5.5 
(3i).  
Mouse irradiation and bone marrow (BM) transplantation 
Donor mice (7-8 weeks old) were euthanized by cervical dislocation. Tibia and fibula were 
collected and BMs were flushed with PBS. 10x10
6
 single BM cells were transplanted to 4-5 
weeks old lethally irradiated (866.3 cGy) recipient mice. Chimeric mice were used in the 
FeCl3 model 3-4 weeks after transplantation. Chimerism was evaluated by western blot of 
DUSP3 in lysates of peritoneal cavity cells. 
Tail bleeding 
Mice were anesthetized with isoflurane. A 3 mm portion of the tail tip was excised and 
submerged in a 37°C water bath. Bleeding was monitored for 15 min.  
Platelet activation, cell lysis, immunoprecipitation, and western blotting 
Mouse WPs were activated with CRP or rhodocytin in Tyrode’s buffer for 30, 60, or 90 s 
under 400 rpm stirring conditions at 37°C. Western blotting and immunoprecipitations were 
performed according to standard procedures.
19
  
Statistical analysis 
Data are presented as mean ± SEM of at least three independent experiments. Data were 
analyzed using unpaired Student’s t-test or ANOVA and the Bonferroni multiple comparison 
test as indicated in each figure legend. Differences in survival were determined using Kaplan-
Meier analysis (log-rank Mantel test). A p-value <0.05 was considered significant. 
Calculations were performed using GraphPad-Prism (GraphPad Software, Inc.). 
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Results 
DUSP3 expression in platelets 
Transcriptomic analysis of platelets from 256 healthy human individuals revealed that 
DUSP3-encoding mRNA is highly expressed in platelets (Figure 1A). Abundance of DUSP3 
in human and mouse platelets was confirmed by western blot analysis (Figure 1B-1C). 
Expression levels of DUSP3 were substantially higher in platelets as compared to B and T 
lymphocytes (Figure 1B-1C), where DUSP3 function had been previously described.
7
 Thus, 
we set out to investigate the role of DUSP3 in platelets using both genetic deletion in mice 
and pharmacological inhibition of DUSP3 in isolated human platelets.   
Activation and aggregation of DUSP3-deficient mouse platelets 
Utilizing our previously generated Dusp3-KO mice,
12
 we confirmed that platelets isolated 
from these animals do not express DUSP3 (Figure 1D). Hematological parameters were 
normal, except for slight but significant differences in monocytes (p<0.05) and mean platelet 
volume (MPV) (p<0.0001) (Supplemental Table 1). Dusp3-KO mice did not show any 
spontaneous bleeding or thrombotic disorders. However, in platelet aggregation assays, 
DUSP3-deficient platelets failed to aggregate in response to low concentrations of collagen 
(0.5 g/mL) and selective GPVI agonists, including CVX (5 ng/mL) and CRP (0.1 g/mL) 
(Figure 2A-C). Additionally, Dusp3-KO platelets exhibited delayed aggregation induced by 
low concentrations of rhodocytin (2.5 and 5 nM), a selective CLEC-2 receptor agonist 
(Figure 2D). GPVI and CLEC-2 surface expression on Dusp3-KO platelets was similar to 
wild-type (WT) platelets (Figures S1A and S2A). In contrast, aggregation induced by ADP 
(5-50 M), thromboxane A2 mimetic U46619 (0.75-2 M), or thrombin (0.01-0.1 U/mL) 
occurred normally (Figure 2E and data not shown), indicating normal G-protein coupled 
receptor (GPCR)-mediated responses.  
 12 
To investigate the mechanism responsible for the impairment of collagen- and CRP-induced 
aggregation of DUSP3-deficient platelets, we analyzed their ability to release granule content 
by measuring P-selectin surface expression, and examined their capacity to activate integrin 
IIb3 by using the JON/A antibody, which is specific for the high-affinity conformation of 
mouse IIb3. In DUSP3-deficient compared to WT platelets, P-selectin expression was 
reduced after stimulation with low concentration of collagen (0.5 g/mL) or various 
concentrations of CRP (0.1, 0.3, and 1 g/mL) (Figure 3A). Integrin IIb3 activation was 
reduced with low concentrations of collagen (0.5 g/mL) and CRP (0.1 g/mL) (Figure 3B). 
Electron microscopy analysis of resting DUSP3-deficient platelets revealed normal 
ultrastructure but a slightly increased number of -granules (Figure 3C and 3D). When 
activated using CVX, degranulation remained incomplete among the few DUSP3-deficient 
platelet aggregates compared to WT (Figure 3C). These findings indicate that DUSP3 
deficiency impairs GPVI- and CLEC-2-dependent mouse platelet activation and aggregation. 
GPVI and CLEC-2 signaling in DUSP3-deficient platelets 
Earlier studies suggested that DUSP3 dephosphorylates ERK1/2 and JNK1/2 but not p38.
7
 
Therefore, we evaluated activation of these MAPKs using phospho-specific antibodies at 
basal levels and after CRP stimulation. No differences in MAPK activation between DUSP3-
deficient and WT platelets were found (Figure S3). We then analyzed global tyrosine 
phosphorylation and found decreased phosphorylation of a 70-kDa band in DUSP3-
deficient compared to WT platelets after CRP or rhodocytin stimulation (Figure 4A and 4C). 
Longer exposure of the pY blot revealed additional bands (at 12, 26, and 40 kDa) with 
decreased phosphorylation in DUSP3-deficient compared to WT platelets after CRP 
stimulation (Figure 4B). We then tested whether the observed change in pY of the 70-kDa 
band may correspond to pY levels in the tyrosine kinase Syk (Mr 72.1 kDa), a key signaling 
molecule in GPVI- and CLEC-2-mediated platelet activation. Indeed, pY of 
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immunoprecipitated Syk was significantly reduced in DUSP3-deficient compared to WT 
platelets after GPVI and CLEC-2 stimulation (p<0.05) (Figures 4D-E and S4A-B). Probing 
total lysates (TLs) of DUSP3-deficient or WT platelets with phospho-Syk-specific antibodies 
revealed that, after activation with CRP, Syk phosphorylation was reduced on the activatory 
residues Tyr-525/526, while phosphorylation of the negative regulatory Tyr-323 was not 
affected (Figures 4F and S4F-G). In rhodocytin-stimulated platelets, Syk phosphorylation 
was reduced on both Tyr-525/526 and Tyr-323 in the absence of DUSP3 (Figures 4G and 
S4H-I).  
Syk is recruited to the GPVI/Fc receptor -chain (FcR) complex via phosphorylation of 
FcR-associated immunoreceptor tyrosine-based activation motifs (ITAMs) by Src-family 
kinases (SFKs), and is then activated via autophosphorylation.
20, 21
 We found that 
phosphorylation of FcR-associated ITAMs was reduced in DUSP3-deficient compared to 
WT platelets in response to CRP (Figures 4H and S4J). In agreement with this observation, 
recruitment of Syk to FcR was impaired in DUSP3-deficient platelets (Figures 4H and S4K). 
Additionally, inducible tyrosine phosphorylation in PLC2, a key signaling molecule 
downstream of Syk, was reduced in both CRP- and rhodocytin-stimulated DUSP3-deficient 
compared to WT platelets (Figures 4I-J and S4L-M). In contrast, activation of SFKs, 
including Lyn, Fyn, and Src, was not altered (Figure S5A and S5B), indicating that the 
reduced activation and recruitment of Syk in DUSP3-deficient platelets was not due to 
aberrant activation of SFKs.  
Collagen-induced aggregation under flow, calcium fluxes, and phosphatidylserine 
exposure in DUSP3-deficient platelets  
To further assess the role of DUSP3 in GPVI-dependent platelet responses, platelet aggregate 
formation and exposure of procoagulant phosphatidylserine (PS) on a collagen surface were 
analyzed in whole mouse blood under flow. The area covered by platelets was reduced by 
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~40% for blood from Dusp3-KO compared to WT mice (Figure 5A and 5B), which was in 
agreement with reduced GPVI activation in DUSP3-deficient platelets.
22
 Accordingly, overall 
PS exposure on adhered platelets was also diminished (Figure 5C and 5D). Because PS 
exposure requires Ca
2+
 influx,
23
 we investigated if Ca
2+
 flux was affected by DUSP3 
deficiency. CVX-induced Ca
2+
 flux was greatly reduced (50%) in DUSP3-deficient compared 
to WT platelets (Figure 5E and 5F). Thapsigargin-induced Ca
2+
 increase occurred normally in 
DUSP3-deficient platelets (Figure S6A), suggesting intact intrinsic Orai 1-mediated store-
operated Ca
2+
 entry. Additionally, there were no differences in Ca
2+
 rises induced by 
thrombin, ADP, or U46619 between WT and Dusp3-KO platelets (Figure S6B-D). These 
data further support a positive role of DUSP3 in GPVI-mediated platelet activation under 
physiological flow conditions. 
DUSP3 deficiency and thrombus formation in vivo 
To evaluate the importance of DUSP3 in platelet function in vivo, we used a model of 
pulmonary thromboembolism induced by intravenous injection of a mixture of collagen and 
epinephrine. About 80% of DUSP3-deficient compared to 45% of WT mice survived (Figure 
6A). Analyses of lung sections revealed significantly decreased numbers of occluded 
microvessels in DUSP3-deficient compared to WT mice (p<0.001) (Figure 6B and 6C). We 
then examined thrombus formation in real-time by intravital microscopy in a model of FeCl3-
induced injury of the carotid arteries. In this model, collagen is exposed to circulating blood, 
and thrombus formation highly depends on GPVI. In DUSP3-deficient mice, blood vessels 
were never occluded due to failure to form stable thrombi, while full occlusion occurred at 8-
10 min after FeCl3 application in WT vessels (Figure 6D and 6G). To test if the defect in 
thrombus formation was specifically due to impaired platelet function, we generated chimeric 
mice by transferring Dusp3-KO bone marrow (BM) (KO>WT) or WT BM (WT>WT) to 
lethally irradiated WT mice. Successful transplantation was evaluated by quantification of 
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DUSP3 expression in peritoneal cell lysates from KO>WT and WT>WT mice (Figure 6F). 
Similar to Dusp3-KO, we found that thrombus formation was severely impaired in blood 
vessels of KO>WT mice (Figure 6E and 6G), confirming that the thrombosis defect in 
DUSP3-deficient animals was due to platelet dysfunction. Importantly, tail bleeding time, a 
measure of primary hemostasis in vivo, was identical for WT and DUSP3-deficient mice 
(Figure 6H). 
Pharmacological inhibition of DUSP3  
In order to corroborate DUSP3 function in human platelets, we investigated the possibility of 
specifically inhibiting DUSP3 activity with small molecules. To identify DUSP3 inhibitors, 
we employed high-throughput screening (HTS), using a colorimetric phosphatase assay with 
p-nitrophenolphosphate (pNPP) as substrate, and screened 291,018 drug-like molecules.
24
 Of 
the 1,524 primary HTS hits (≥50% inhibition), 1,048 compounds were available from 
BioFocus DPI and ordered for confirmatory assays. The hits were tested in two 
reconfirmation single-dose screens in triplicate, using both the primary colorimetric assay 
and an orthogonal fluorescent assay with 3-O-methylfluorescein phosphate (OMFP) as 
substrate. Compounds with an average of ≥50% inhibition of DUSP3 activity were further 
tested in a 10-point dose-response assay in both colorimetric and fluorescent formats. IC50 
values were determined, and 67 ‘cross-active’ compounds were identified with IC50 values 
<20 μM in both assays. Upon visual inspection of each molecule, 32 compounds were 
discarded from further consideration because of their known promiscuous PTP inhibitory 
activity. The remaining 35 compounds were taken into selectivity profiling studies for further 
prioritization. Compound selectivity for inhibiting DUSP3 over the related DUSP6 and three 
additional PTPs, HePTP, LYP, and STEP, was evaluated (Supplemental Table S2).  
Based on the selectivity and potency of compounds, two scaffolds were selected for 
structure-activity relationship (SAR) studies: MLS-0103602 and MLS-0049585 
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(Supplemental Table S2). MLS-0103602 (IC50 = 0.37 μM) was the most potent inhibitor with 
some degree of selectivity for DUSP3; MLS-0049585 (IC50 = 2.68 μM) exhibited the best 
selectivity for DUSP3. Based on the benzothioamide structure of MLS-0103602, 37 analogs 
were tested and counterscreened. All analogs were at least an order of magnitude less potent 
than the original hit, with no improvement of selectivity, leading to the termination of this 
series (data not shown). In contrast, several analogs containing the N-(benzo[d]thiazol-2-yl)-
5-phenyl-1,3,4-oxadiazol-2-amine structure of MLS-0049585 with similar or even better 
potency could be identified (Supplemental Table S3). The four most potent compounds were 
selected for testing in human platelets. Inhibition of platelet aggregation was assessed using 
platelets collected from three healthy donors. In these experiments, MLS-0437605 (Figure 
7A) efficiently inhibited platelet aggregation in response to CRP and rhodocytin, but not after 
stimulation with thromboxane (Figure 7B and 7C). Tests on platelets from WT mice yielded 
similar results (Figure 7D). In contrast, MLS-0437605 only minimally affected aggregation 
of DUSP3-deficient platelets (Figure 7D). Selectivity was further evaluated against 10 
additional PTPs (Table 1). In these assays, MLS-0437605 showed excellent selectivity for 
DUSP3 over the vast majority of PTPs tested. Importantly, there was good selectivity of 
MLS-0437605 for DUSP3 over DUSP22 (7-fold), another DSP that is highly expressed in 
platelets (Figure 1A). We next examined the effect of MLS-0437605 on GPVI- and CLEC-2-
induced signaling in human platelets. Global tyrosine phosphorylation was analyzed on TLs 
from resting or activated platelets. MLS-0437605 caused a decrease in pY of a 70-kDa band 
after stimulation with CRP or rhodocytin (Figure 7E and 7F). Tyrosine phosphorylation of 
immunoprecipitated Syk and PLC2 was also reduced by MLS-0437605 (Figure 7G and 7H). 
These data demonstrate that pharmacological inhibition of DUSP3 activity in human platelets 
similarly affects platelet signaling as DUSP3 deficiency in Dusp3-KO platelets. 
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Discussion  
This is the first study implicating a member of the PTP subfamily of dual-specificity 
phosphatases in GPVI- and CLEC-2-induced signaling. Motivated by our finding that 
DUSP3 is highly expressed in human and mouse platelets, we utilized Dusp3-KO mice to 
study the role of this phosphatase in hemostasis and thrombosis. DUSP3-deficient mice were 
more resistant to pulmonary thromboembolism than their WT littermates. Thrombus 
formation was strongly impaired in the model of FeCl3-induced injury of carotid artery in a 
platelet-specific manner. Intriguingly, DUSP3-deficient mice did not bleed spontaneously 
and showed normal tail bleeding times. These findings suggest that DUSP3 plays a key role 
in arterial thrombosis, but is dispensable for primary hemostasis.  
Ex vivo, upon platelet stimulation with low concentrations of collagen, CVX, CRP, or 
rhodocytin, DUSP3 deficiency resulted in defective platelet aggregation, granule secretion, 
and integrin IIb3 inside-out activation. In contrast, platelet activation mediated by GPCR 
agonists was not affected. DUSP3 deficiency led to a reduction of thrombus formation on 
collagen-coated surface under arterial shear, as well as lower PS exposure at the surface of 
adhered platelets. These data indicate that both GPVI- and CLEC-2-mediated platelet 
activation are impaired in DUSP3-deficient platelets.
25-27
 DUSP3 was dispensable for integrin 
IIb3 outside-in signaling, as indicated by unaltered fibrin clot retraction (data not shown). 
Dusp3-KO mice exhibited levels of thrombus formation comparable to the previously 
reported GPVI-KO/FcR28-30 CLEC-2-KO,31 CLEC-2-depleted,26 GPVI-depleted,32 and 
CLEC-2/GPVI-depleted mice.
27
 Similar to our findings in DUSP3-deficient mice, GPVI-KO 
and CLEC-2-KO mice do not exhibit prolonged bleeding time.
28, 31, 33
 DUSP3-deficient mice 
were also protected against pulmonary thromboembolism induced by a mixture of collagen 
and epinephrine, similar to GPVI-KO mice.
33
 
At the molecular level, phosphorylation of the previously reported DUSP3 substrates ERK1/2 
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and JNK1/2
7
 was not affected by DUSP3 deficiency, suggesting that signaling defects in 
DUSP3-deficient platelets are independent of the ERK1/2 and JNK1/2 pathways. However, 
we cannot exclude the possibility of functional or compensatory redundancies between 
DUSP3 and other phosphatases. 
GPVI and CLEC-2 signaling pathways share many similarities, including the activation of 
Syk, PLCγ2, and adapter proteins such as LAT and SLP-76.34 However, there is also a 
significant difference: in GPVI-stimulated platelets, SFKs initiate signaling through 
phosphorylation of the FcR-associated ITAMs, leading to binding and activation of Syk;20, 21 
in contrast, signaling through CLEC-2 depends on phosphorylation of CLEC-2 by Syk in an 
SFK-independent manner.
35
 Because DUSP3 deficiency limits platelet activation in response 
to both GPVI and CLEC-2 stimulation, SFK function is likely not controlled by DUSP3, 
which is also supported by our data showing that pY in SFKs is not altered in Dusp3-KO 
platelets. On the contrary, Syk may be directly or indirectly targeted by DUSP3. Intriguingly, 
however, DUSP3 deficiency decreased pY levels in Syk. Further, no hyperphosphorylated 
protein could be identified in pY blots of TLs from DUSP3-deficient platelets. This raises the 
question whether phosphoserine (pS) or phosphothreonine (pT) in Syk or other protein(s) 
may be targeted by DUSP3, a dual-specificity phosphatase able to dephosphorylate both pY 
and pS/pT. Given the limited recognition sites of available pS/pT antibodies, future studies 
using quantitative phospho-proteomics analysis will be necessary to address this question.  
Platelet binding to von Willebrand factor (vWF) via GPIbα allows engagement of the 
collagen receptors GPVI and α2β1, leading to platelet arrest and subsequent platelet thrombus 
formation. The vWF-GPIb axis also induces GPVI dimerization, resulting in direct 
enhancement of GPVI interaction with collagen.
36
 However, platelets from Dusp3-KO mice 
exhibit normal binding to vWF-coated surface under flow (Supplementary Figure S7), 
suggesting intact GPIb signaling in these animals. Interestingly, a recent study by 
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Nieswandt’s group showed that combined depletion of GPVI and CLEC-2 was sufficient to 
abrogate arterial thrombosis in mice.
27
 Thus, the defects observed in DUSP3-deficient 
platelets on CLEC-2- and GPVI-induced signaling are sufficient to explain the impaired 
thrombus formation in Dusp3-KO mice. 
Finally, platelets are anucleate cells that are not amenable to RNA interference or 
recombinant DNA technologies. Thus, in order to corroborate our findings in human cells, 
we utilized a chemical genomics approach. Specifically, a small-molecule inhibitor of 
DUSP3 was identified via HTS of a large chemical library and subsequent SAR studies. 
Previously reported DUSP3 inhibitors suffer from either poor selectivity, lack of efficacy, or 
both,
37-41
 or cause immediate spontaneous aggregation of platelets (data not shown).
42
 Thus, 
we developed a novel, specific, and efficacious inhibitor, which we used to inhibit DUSP3 
function in human washed platelets. Similar to DUSP3 deficiency in murine cells, inhibition 
of DUSP3 activity in human platelets led to suppression of platelet aggregation, specifically 
in response to CRP and rhodocytin, but not in response to the GPCR agonist thromboxane. 
MLS-0437605 is a drug-like compound
43
 and may serve as the basis for the development of 
potential therapeutics targeting DUSP3 for the treatment of arterial thrombosis.  
Conclusion 
We demonstrated that DUSP3 is a key signaling molecule for GPVI- and CLEC-2-induced 
platelet activation. We developed a specific small-molecule inhibitor of DUSP3, which 
efficiently inhibited human platelet activation in vitro. Given that Dusp3-KO mice remain 
healthy, do not exhibit any spontaneous phenotype, and do not suffer from increased bleeding 
events, our findings may lead to a novel antiplatelet therapy.  
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Figure legends 
Figure 1. DUSP3 expression in human and mouse platelets. (A) Microarray data of mRNA 
expression of 17 atypical DSPs in human platelets isolated from 256 healthy volunteers. Each 
open circle represents one individual. DNM3 was used as positive control for platelet 
expressed mRNA. Data are presented as ratio of the fluorescence intensity for the DSP probe 
of interest and the mean fluorescence intensity for the housekeeping genes of each sample. A 
negative value corresponds to an expression bellow background level. Mean ± SEM are 
shown. (B-D) DUSP3 protein expression in human B and T lymphocytes and in platelets 
isolated from peripheral blood (B); in mouse splenic B and T cells and in washed platelets 
(C); and in WT and Dusp3-KO mouse washed platelets (D). Western blot analysis was 
performed using anti-human (B) and anti-mouse DUSP3 (C-D). GAPDH was used as loading 
control. Representative blots of three independent experiments are shown.  
Figure 2. DUSP3-deficient platelets exhibit impaired GPVI- and CLEC-2-mediated platelet 
aggregation. (A-E) Washed platelets prepared from WT or Dusp3-KO mice were stimulated 
with collagen (0.5 and 1 g/mL) (A), CRP (0.1, 0.3, and 1 g/mL) (B), CVX (5, 10, and 100 
ng/mL) (C), rhodocytin (2.5, 5, and 10 nM) (D), or thromboxane A2 analog U46619 (1 M), 
thrombin (0.05 U/mL), or ADP (20 M) (E). Representative platelet aggregation curves of 
three individual experiments are shown.  
Figure 3.  Impaired GPVI-mediated platelet activation in DUSP3-deficient platelets. (A-B) 
Washed platelets from WT or Dusp3-KO mice were stimulated with 0.1, 0.3, or 1 g/mL 
CRP or 0.5 or 1 g/mL collagen under non-stirring conditions, or left untreated. Surface 
expression of P-selectin and active integrin IIb3 (JON/A) was quantified by flow cytometry. 
Mean fluorescence intensity histograms for P-selectin (A) and JON/A (B) are shown. Data 
were analyzed using ANOVA and the Bonferroni multiple comparison test and represent 
mean ± SEM of four independent experiments performed on platelet pools from three mice 
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each; *p< 0.05, **p< 0.01. (C) Electron microscopy analysis of WT and Dusp3-KO washed 
platelets. Platelet ultrastructure was visualized in resting state or upon CVX stimulation (100 
ng/mL). (D) Scatter plots of alpha and dense granules counted on five separated micrographs. 
Data were analyzed using unpaired Student t-test and represent mean ± SEM of three 
independent experiments performed on platelet pools from three mice; *p< 0.05, **p< 0.01.    
Figure 4. DUSP3-deficiency impairs Syk tyrosine phosphorylation. TLs were prepared from 
WT or Dusp3-KO mice platelets. Cells were non-activated, CRP- (0.3 g/mL) or rhodocytin-
activated (10 nM) for 30, 60, or 90 s. (A-C) Western blot analysis with anti-pY antibody 
(4G10) and with ERK1/2 (A) or GAPDH (C) as loading control. Arrows in (B) indicate 
unknown protein bands with attenuated pY levels in DUSP3-deficient platelets. (D-E) 
Representative pY blot of Syk immunoprecipitates from TLs of CRP- (D) or rhodocytin-
activated (E) platelets. (F-G) Representative blot of Syk phosphorylation on Tyr-323 and 
Tyr-525/526 in CRP- (F) or rhodocytin-activated (G) platelets. Normalization was performed 
using total Syk. (H) pY and Syk western blots on FcRimmunoprecipitates. (I-J) pY blot of 
PLC immunoprecipitates from TLs of CRP- (I) or rhodocytin-activated (J) platelets. 
Results shown are representative of 3 independent experiments performed on platelet pools 
from three mice each. 
Figure 5. Impaired platelet aggregate formation on whole blood from DUSP3-deficient mice. 
(A-D) Anticoagulated blood from WT or Dusp3-KO mice was perfused over collagen-coated 
coverslip through a parallel-plate transparent flow chamber at a wall-shear rate of 1000 s
-1
 for 
4 min. Representative phase-contrast images of fixed platelets (A) and percentages of surface 
coverage by platelets (B) are shown. Exposure
 
of phosphatidylserine (PS) was detected by 
post-perfusion with
 
heparin and OG488-labeled Annexin-V-containing rinsing buffer. 
Representative fluorescent images (C) and percentage of area coverage by labeled platelets 
(D) are shown. (E-F) Intracellular Ca
2+
 increase in WT and Dusp3-KO platelets upon CVX 
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stimulation (50 ng/mL). Representative curves (E) and histogram depicting the area under the 
curve (F) are shown. WT values are arbitrarily set to 100%. Unpaired Student’s t-test was 
used for comparison. Results are representative of five independent experiments performed 
on platelet pools from three mice each. 
Data represent mean ± SEM of three independent experiments; **p<0.01, ***p<0.001.    
Figure 6. Impaired arterial thrombosis and preserved hemostasis in DUSP3-deficient mice. 
(A-C) Pulmonary thromboembolism induced by injection of a mixture of collagen and 
epinephrine. Mortality incidence rates were compared using Kaplan-Meir with log-rank test 
(n=20 for KO and n=23 for WT mice) (A), quantification of the number of occluded vessels 
per visual field on lung sections from WT and Dusp3-KO mice (B), and representative field 
on lung sections from WT and Dusp3-KO mice (C) are shown. Data (from three to six lung 
sections from three mice of each group) were analyzed using unpaired Student’s t-test; 
**p<0.01. (D-E) FeCl3 injury of carotid arteries. Representative snapshot images in WT and 
Dusp3-KO mice (D), and in WT mice transplanted with WT (WT>WT) or with Dusp3-KO 
(KO>WT) BM cells (E) are shown. (F) Western blot analysis of DUSP3 expression in 
peritoneal TLs from WT>WT and KO>WT BM-transplanted mice used in the FeCL3 assay. 
Normalization was performed using GAPDH. (G) Numbers of intact and partially occluded 
vessels are shown for four mice of each group. (H) Tail bleeding time of WT (dark circle) 
and Dusp3-KO (open circle) mice. Each dot/circle represent one mouse. Results are 
presented as mean ± SEM. 
Figure 7. Specific DUSP3 inhibitor MLS-0437605 inhibits platelet activation in response to 
CRP and rhodocytin. (A) Chemical structure and key properties of MLS-0437605. (B-D) 
Washed human platelets (B/C) or WT and Dusp3-KO mice washed platelets (D) were pre-
incubated for 30 min with DMSO (vehicle) or with MLS-0437605 (3.7 M), before 
stimulated with CRP (0.5 g/mL), rhodocytin (5 or 10 nM), or U46619 (0.15 g/mL). 
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Representative platelet aggregation curves (B/D) and quantification of platelet aggregation 
from three healthy human donors (C) are shown. Results were analyzed using one-way 
ANOVA Bonferroni multiple comparison test and are presented as mean ± SEM; **p<0.01. 
(E-J) TLs were prepared from vehicle- or MLS-0437605-pretreated human platelets. Cells 
were non-activated or activated with CRP or rhodocytin for the indicated times. Western blot 
analysis was performed with 4G10 antibody for global pY of CRP (E) and rhodocytin (F) 
activated platelets. ERK1/2 was used as a loading control. (G-H) Representative pY blot of 
Syk immunoprecipitates from TLs of CRP- (G) or rhodocytin-activated (H) platelets. (I-J) 
pY blot of PLC immunoprecipitates from TLs of CRP- (I) or rhodocytin-activated (J) 
platelets. Data are representative of two individual healthy donors. 
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Table 1. Selectivity of DUSP3 inhibitor MLS-0437605 
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Methods and reagents 
Antibodies, reagents, and recombinant PTPs 
Fluorescein isothiocyanate (FITC)-conjugated anti-P-selectin, and phycoerythrin (PE)-
conjugated anti-active integrin !IIb"3 (JON/A) antibodies were from Emfret Analytics 
(Würzburg, Germany). Anti-Fyn, anti-phosphotyrosine antibody (4G10) and anti-FcR# 
subunit and mouse anti-rabbit light chain specific-HRP were from Millipore (Billecrica, 
MA). Antibodies against Syk, Syk p-Tyr 525/526, Syk p-Tyr 323, Lyn p-Tyr-507, ERK 
(p44/42), p-ERK1/2 (Thr202/Tyr204), p38 MAPK, and p-p38 (Thr180/Tyr182) were from 
Cell Signaling (Danvers, MA). Anti-Src p-Tyr-416/418, anti-Src p-Tyr-529, and anti-Src pan 
antibodies were from Fisher Scientific (Erembodegem, Belgium). Anti-Fyn p-Tyr-530 was 
from Abcam (Cambridge, UK). Anti-Lyn and anti-DUSP3/VHR used for mice samples (sc-
8889) were from Santa-Cruz (Santa Cruz, CA). Anti-DUSP3/VHR antibody used for human 
samples (Clone 24/VHR), FITC-conjugated anti-CD3, PE-conjugated anti-B220, APC-Cy7-
conjugated anti-Ly6G, PerCP-Cy5-conjugated anti-NK1.1 and Alexa-647 conjugated anti-rat 
antibodies were from BD Biosciences (Erembodegem, Belgium). Anti-CLEC2 antibody 
(clone 17D9) was from Serotec (Puchheim, Germany). Anti-vWF antibody was from Dako 
(Heverlee, Belgium). Goat anti-mouse kappa HRP-conjugated was from Southern Biotech 
(Birmingham, AL). 
D-Phe-Pro-Ala-chloromethylketone (PPACK) was from Calbiochem (San Diego, CA). 
Fibrillar-type I equine tendon collagen was from Nycomed (Zurich, Switzerland). Bovine 
thrombin, ADP, and U46619 were from Sigma-Aldrich (Diegem, Belgium). Cross-linked 
collagen-related peptide (CRP) was provided by Prof. R.W. Farndale’s laboratory. 
Rhodocytin was purified from C. rhodostoma venom as described previously. [1] Annexin 
A5 labeled with Oregon Green OG488 and Fura-2 were from Molecular Probes (Leiden, the 
Netherlands). Convulxin was obtained from Kordia (Leiden, the Netherlands).!
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Para-nitrophenyl phosphate (pNPP), 3-O-methylfluorescein phosphate (OMFP), and 
dithiothreitol (DTT), and sodium orthovanadate (Na3VO4) were purchased from Sigma-
Aldrich. Biomol Green reagent was from Biomol Research Laboratories, Inc. (Plymouth 
Meeting, PA). Compounds for follow-up studies were purchased from Specs or ChemBridge. 
All compounds had a purity of >95% (verified by LC/MS and 1H-NMR). Compounds chosen 
for cell-based assays were additionally repurified to >99% purity, and activity of the 
repurified substance was confirmed. All other chemicals and reagents were of the highest 
grade commercially available. Recombinant DUSP3, DUSP6, DUSP22, HePTP, LYP, PTP-
SL, and STEP were expressed in E. coli and purified as described previously. [2-4] 
Recombinant CD45, TCPTP, LAR, and PTP1B were from Biomol Research Laboratories, 
Inc (Plymouth Meeting, PA, USA). 
Platelet RNA sampling and Microarray   
Platelet rich plasma (PRP) was prepared from citrate anticoagulated-blood. Depletion of 
CD45+ leukocytes was performed before total RNA extraction from freshly purified platelets 
using RNeasy Mini Kit on a QIAcube (Qiagen, Venlo, The Netherlands) and stored at -80°C 
until used. RNA was quantified by absorbance measurement, and 200 ng of RNA were 
engaged in reverse transcription with oligo-dT primers (Superscript III RT, Invitrogen), prior 
to biotin labeling and amplification using the TargetAmp Nano-g Biotin-aRNA Labeling Kit 
for the Illumina System (Epicentre). Biotin-labeled aRNA were purified using the RNeasy 
MinElute Cleanup Kit (Qiagen) and 400 ng were hybridized on Human HT-12 v4 arrays 
(Illumina) following the recommendations of the manufacturer. Arrays were scanned on an 
iScan microarray scanner (Illumina). Internal controls of the arrays were analyzed for quality 
control. Cell-specific expression markers were analyzed in all samples, ruling out 
contamination of platelet RNA with leukocyte RNA. Indeed, in this assay, comparison of the 
different DSPs mRNA levels is not possible.  The raw fluorescence intensities for the probes 
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corresponding to the atypical DSPs have been corrected for the fluorescence background 
signal for each sample on the array by subtracting the fluorescence intensity of the negative 
control probes on the array. The data have then been normalized by dividing the intensity for 
each probe in each sample by the mean fluorescence intensity of 7 housekeeping genes 
(EEF1A1, UBC, ACTB, RPS9, GAPDH, TUBB2A and TXN) in the same sample. The data 
are presented as a ratio of the fluorescence intensity for the probe of interest and the mean 
fluorescence intensity for the housekeeping genes of each sample. A negative value 
corresponds to a lack of detection of the expression of the gene (expression level below the 
background). 
Chemical Library Screening for DUSP3 inhibitors 
DUSP3 HTS was performed within the MLPCN network, PubChem AID 1654. A total of 
291,018 compounds (comprising the full MLPCN library at the time of screening) were 
screened at a concentration of 13.3 µM. A colorimetric phosphatase assay was set up in 1536-
well format, using the general phosphatase substrate pNPP.[5, 6] The assay buffer contained 
20 mM Bis-Tris (pH 6.0), 1 mM DTT, and 0.005% Tween-20. A detailed protocol of the 
HTS assay was published previously.[7] 
Single-concentration confirmatory assays for DUSP3 hits using OMFP.  
Phosphatase activity was measured in triplicate in a 1536-well format assay system, using the 
fluoresceine-based phosphatase substrate OMFP. The assay buffer contained 20 mM Bis-Tris 
(pH 6.0), 1 mM DTT, and 0.005% Tween-20. For a detailed protocol please see ref. 7. 
Selectivity profiling assays. 
Selectivity of compounds for inhibiting DUSP3 was tested against 10 additional PTPs using a 
96-well format dose-response assay system with OMFP as substrate.[2] Enzyme 
concentrations were as follows: DUSP3, 2 nM; DUSP6, 10 nM; DUSP22, 10 nM; PTP-SL, 5 
nM; HePTP, 5 nM; LYP, 5 nM; TCPTP, 2 nM; CD45, 2 nM; LAR, 1U/mL; STEP, 5 nM; 
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and PTP1B, 5 nM. OMFP was used at concentrations equal to the corresponding Km values: 
DUSP3, 13 !M; DUSP6, 50 !M; DUSP22, 2.2 !M; PTP-SL, 28 !M; HePTP, 117 !M; LYP, 
185 !M; TCPTP, 56 !M; CD45, 347 !M; LAR, 78 !M; STEP, 32 !M; and PTP1B, 99 !M. 
The initial rate was determined using a FLx800 micro plate reader (Bio-Tek Instruments, 
Inc.), an excitation wave length of 485 nm and measuring the emission of the fluorescent 
reaction product 3-O-methylfluorescein at 525 nm. The nonenzymatic hydrolysis of the 
substrate was corrected by measuring the control without addition of enzyme. IC50 values for 
each enzyme were determined as described previously.[2] 
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Figure Legends 
Figure S1. Surface expression of major platelet receptors on Dusp3-deficient platelets.  
Resting WT and Dusp3-KO platelets were stained with (A) anti-GPVI-FITC, (B) anti-CD41-
FITC, (C) anti-CD42C/GPIb-FITC, and (D) anti-CD42D/GPV-FITC and analyzed by flow 
cytometry. Anti-mouse IgG-FITC (grey line) was used as a negative control antibody for the 
staining. Representative histograms with the mean fluorescence intensity (MFI) for WT (dark 
line) and Dusp3-KO (dashed line) are shown for each staining.  
Figure S2. CLEC-2 surface expression in platelets and mononucleated cells. (A) Resting WP 
from WT and Dusp3-KO platelets were stained with anti-CLEC-2 antibody followed by a 
secondary staining using Alexa-647 conjugated anti-rat antibody and FITC-conjugated anti-
CD41. A rat-anti-mouse antibody was used as a negative control (grey line). (B) Resting 
spleenocytes from WT and Dusp3-KO mice were stained using PE-conjugated anti-B220, 
FITC-conjugated anti-CD3, APC-Cy7-conjugated anti-Ly6G, PerCP-Cy5-conjugated anti-
NK1.1 and anti-CLEC-2 followed by Alexa-647 conjugated anti-rat antibody. CD3+ (T 
lymphocytes), B220+ (B Lymphocytes), Ly6G+ (Neutrophils) and NK1.1+ (NK cells) were 
separately gated out of total live cells and analyzed for the expression of CLEC-2. 
Representative histograms with the % of Max of the mean fluorescence intensity for WT 
(dark line) and Dusp3-KO (grey line) are shown for each staining. 
Figure S3. MAPKs activation in Dusp3-KO platelets. Total cell lysates (TCLs) were 
prepared from CRP (0.3 µg/mL) activated WT or Dusp3-KO mouse platelets. Cells were 
non-activated or activated for 30, 90, and 300 s (for MAPKs) or 30, 60, and 90 s (for SFKs) 
with CRP. Equal amounts of protein were resolved by SDS-PAGE, and western blot analysis 
was performed using: Anti-phospho-ERK1/2 (Thr202/Tyr204), anti-JNK1/2 
(Thr183/Tyr185), and anti-phospho-p38 (Thr180/Tyr182). Anti-ERK1/2, anti-JNK1/2, and 
anti-p38 were used as loading controls.   
 9 
Figure S4. Quantification of Syk, FcR!, and PLC! tyrosine phosphorylation and recruitment 
of Syk to FcR!. Densitometric analysis of results presented in Figure 4 for tyrosine 
phosphorylation of immunoprecipitated Syk (Figure 4D and 4E) in CRP-activated conditions 
(A) and in rhodocytin stimulated conditions (B). Quantification of Syk phosphorylation on 
Tyr-323 and Tyr-525/526 (shown in Figure 4F and 4G) in CRP (C-D) or rhodocytin (E-F) 
activated platelets. Normalization was performed using total Syk. (G) Quantification of 
tyrosine phosphorylation (4G10) western blots on FcR# immunoprecipitates. (H) 
Quantification of Syk recruitement to Fc#R. (I-J) Statistical analysis of tyrosine 
phosphorylation (4G10) of PLC#2  immunoprecipitates from equal amounts of TCLs from 
CRP (I) or rhodocytin (J) activated platelets. Data were analyzed using Anova Bonteferroni 
multiple comparison test and are presented as mean ± SEM. Statistical analyses are shown for 
three independent experiments, each experiment was performed using pooled platelets from 
three mice. 
Figure S5. SFK activation in Dusp3-KO platelets. Total cell lysates (TCLs) were prepared 
from CRP (0.3 µg/mL) or rhodocytin (10nM) activated WT or Dusp3-KO mouse platelets. 
Cells were non-activated or activated for 30, 60, and 90 s with CRP (A) or with rhodocytin 
(B). Equal amounts of protein were resolved by SDS-PAGE, and western blot analysis was 
performed using: Anti-phospho-Src (Tyr416), anti-phospho-Src (Tyr529), anti-phospho-Fyn 
(Tyr530), or anti-phospho-Lyn (Tyr507). Anti-Src and anti-Fyn were used as loading 
controls. Data were analyzed using Anova Bonteferroni multiple comparison test and are 
presented as mean ± SEM. Results are representative of three independent experiments. 
Figure S6. Thapsigargin induced store mediated Ca2+ entry and GPCR agonist-triggered 
intracellular Ca2+ increase in Dusp3-KO platelets. (A) Fura-2 loaded platelets were 
stimulated with thapsigargin (200 nM) before adding 500 mM CaCl2. (B-D) Platelets were 
stimulated with thrombin (IIA, 10 nM) (B), ADP (20 mM) (C), or TXA2 mimetic U46619 (1 
 10 
mM) (D). Traces are representative of three independent experiments. 
Figure S7. Platelet aggregate formation on whole blood on vWF coated surface.  
Anticoagulated blood from WT or Dusp3-KO mice was perfused over vWF-coated coverslip 
(1.4 µg) through a parallel-plate transparent flow chamber at a wall-shear rate of 1000 s-1 for 
4 min. Representative phase-contrast images of fixed platelets (A) and percentages of surface 
coverage by platelets (B) are shown. Results were analyzed using unpaired Student t-test. 
Data represent mean ± SEM of three independent experiments; ns=non significant. 
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Table S1. Hematological parameters of WT and DUSP3-KO mice. 
 
 
  
 WT (n=19) DUSP3-KO (n=16) P Value 
WBC (x103/mL) 4.353±0.3183 4.234±0.3369 0.7998 (ns) 
Lymphocytes (x103/mL) 3.339±0.2416 3.299±0.2678 0.9134 (ns) 
Neutrophils (x103/mL) 0.6053±0.0811 0.5575±0.0699 0.6663 (ns) 
Monocytes (x103/mL) 0.1841±0.01791 0.1296±0.0130 0.0232 (*) 
Eosinophils (x103/mL) 0.01864±0.008395 0.02956±0.01254 0.4567 (ns) 
Basophils (x103/mL) 0.2019±0.01793 0.1999±0.01662 0.9356 (ns) 
Platelets (x103/mL) 835 ± 27 905 ± 23 0.0577 (ns) 
Hgb (g/dL) 10.73±0.2125 11.24±0.1594 0.0729 (ns) 
HCT (%) 34.93±0.5836 36.49±0.5274 0.0584 (ns) 
MPV 5.475±0,046 5.099±0,06 <0.0001 (***) 
 12 
Table S2. Potency and selectivity of 35 selected DUSP3 inhibitors. IC50 values are in µM; 
phosphatase substrates used are given in parentheses (OMFP or pNPP). 
Compound 
ID 
Structure 
DUSP3 
(OMFP) 
DUSP3 
(pNPP) 
DUSP6 
(OMFP) 
HePTP 
(OMFP) 
LYP 
(OMFP) 
STEP 
(OMFP) 
MLS-
0326173 
 
<1.23 <1.23 <1.23 n/d n/d n/d 
MLS-
0322508 
 
<1.23 <1.23 <1.23 n/d n/d n/d 
MLS-
0347633 
 
<1.23 <1.23 1.36 n/d n/d n/d 
MLS-
0103602 
 
<1.23 3.34 >100 <1.23 n/d 5.11 
NO
O
O
NH
S
O
O
N
O
O
O NH S
F
N
O
O
O
HN
S
O
OH
SN
 13 
MLS-
0044298 
 
1.27 3.53 >100 <1.23 <1.23 n/d 
MLS-
0330044 
 
2.09 4.01 >100 <1.23 21 3.86 
MLS-
0307023 
 
2.44 4.31 >100 <1.23 >100 14.5 
MLS-
0312565 
 
2.52 1.3 27.3 <1.23 2.13 n/d 
MLS-
0049585 
 
2.68 3.02 >100 8.33 42 >100 
N
N
O
S
S
N
H2N
O
NH
S
N
N
Cl
ClCl
S
HN
HN
Cl
S
O
O
OHO
N
HN
NH
N
O
N
N
NH
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O
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O
 14 
MLS-
0029484 
 
3.18 5.73 >100 <1.23 n/d n/d 
MLS-
0146252 
 
3.2 <1.23 30.9 <1.23 2.88 n/d 
MLS-
0100722 
 
3.25 1.89 7.9 n/d n/d n/d 
MLS-
0273250 
 
4.76 8.52 >100 n/d 9.73 6.57 
MLS-
0274366 
 
4.8 2.43 >100 2.52 <1.23 n/d 
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N
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NSS
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O OH
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N
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 15 
MLS-
0266887 
 
4.87 <1.23 69.8 <1.23 n/d n/d 
MLS-
0350105 
 
5.01 <1.23 40.9 <1.23 1.51 n/d 
MLS-
0249773 
 
5.02 4.04 10.1 n/d n/d n/d 
MLS-
0109562 
 
5.35 8.8 >100 <1.23 n/d 17 
MLS-
0266851 
 
5.44 3.69 68.6 <1.23 <1.23 2.18 
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O O
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MLS-
0276952 
 
6.14 4.36 17.2 n/d n/d n/d 
MLS-
0383777 
 
6.72 1.88 62.7 <1.23 n/d n/d 
MLS-
0250197 
 
7.26 2.27 9.04 n/d n/d n/d 
MLS-
0276195 
 
8.44 5.27 25.6 n/d 22.9 4.09 
MLS-
0350978 
 
9.18 6.94 32.3 <1.23 10.6 n/d 
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MLS-
0265159 
 
10.5 1.71 7.01 n/d n/d n/d 
MLS-
0343544 
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Table S3. SAR studies for compound MLS-0049585. 
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